B-cell receptor-guided delivery of peptide-siRNA complex for B-cell lymphoma therapy

Cancer Cell International

Volumn 15, Issue 1, 2015, Pages

  Migliaccio, Nunzia ^a   Palmieri, Camillo ^b   Ruggiero, Immacolata ^a   Fiume, Giuseppe ^b   Martucci, Nicola M ^a   Scala, Iris ^a   Quinto, Ileana ^b   Scala, Giuseppe ^b   Lamberti, Annalisa ^a   Arcari, Paolo ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

B lymphoma cells; Id peptide; Minimal residual disease (MRD); Peptide engineering; Peptide siRNA complex

Indexed keywords

ARGININE; B LYMPHOCYTE RECEPTOR; FLUORESCENT DYE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; IMMUNOGLOBULIN IDIOTYPE; MESSENGER RNA; PROTEIN BCL 2; SMALL INTERFERING RNA;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; B CELL LYMPHOMA; CARBOXY TERMINAL SEQUENCE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOFLUOROMETRY; DOWN REGULATION; DRUG DELIVERY SYSTEM; DRUG SAFETY; DRUG SELECTIVITY; DRUG TARGETING; GENE SILENCING; GENETIC ENGINEERING; INTERNALIZATION; LYMPHOMA CELL; MOUSE; NONHUMAN; PROTEIN BINDING; PROTEIN EXPRESSION;

EID: 84930200860     PISSN: None     EISSN: 14752867     Source Type: Journal    
DOI: 10.1186/s12935-015-0202-4     Document Type: Article

References (25)

1. Wang J, Lu Z, Wientjes MG, Au JL. Delivery of siRNA Therapeutics: barriers and carriers. AAPS J. 2010;12:492-503.
2. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nature Nanotech. 2007;2:751-60.
3. Di Martino MT, Campani V, Misso G, Gallo Cantafio ME, Gullà A, Foresta U, et al. In vivo activity of MiR-34a mimics delivered by stable nucleic acid lipid particles (SNALPs) against multiple myeloma. PLoS One. 2014;9, e90005.
4. Min K, Song KM, Cho M, Chun YS, Shim YB, Kua JK, et al. Simultaneous electrochemical detection of both PSMA (+) and PSMA (-) prostate cancer cells using an RNA/peptide dual-aptamer probe. Chem Commun. 2010;46(30):5566-8.
5. Bruno JG. A review of therapeutic aptamer conjugates with emphasis on New approaches. Pharmaceuticals. 2013;6:340-57.
6. Martin ME, Rice KG. Peptide-guided gene delivery. AAPS J. 2007;9:E18-29.
7. Dorsett Y, Tuschl T. siRNAs: applications in functional genomics and potential as therapeutics. Nat Rev Drug Discov. 2004;3:318-29.
8. Dykxhoorn DM, Palliser D, Lieberman J. The silent treatment: siRNAs as small molecule drugs. Gene Ther. 2006;13:541-52.
9. Järver P, Coursinde T, EL Andaloussi S, Godfrey C, Wood MJA, Gait MJ. Peptide-mediated cell and in vivo delivery of antisense oligonucleotides and siRNA. Mol Ther Nucleic Acids. 2012;1, e27.
10. De Angelis F, Pujia A, Falcone C, Iaccino E, Palmieri C, Liberale C, et al. Water soluble nanoporous nanoparticle for in vivo targeted drug delivery and controlled release in B cells tumor context. Nanoscale. 2010;2:2230-6.
11. Palmieri C, Falcone C, Iaccino E, Tuccillo FM, Gaspari M, Trimboli F, et al. In vivo targeting and growth inhibition of the A20 murine B-cell lymphoma by an idiotype-specific peptide binder. Blood. 2010;2:226-38.
12. Kim KJ, Kanellopoulos-Langevin C, Merwin RM, Sachs DH, Asofsky R. Establishment and characterization of BALB/c lymphoma lines with B cell properties. J Immunol. 1979;122:549-54.
13. Glimcher LH, Kim KJ, Green I, Paul WE. Ia antigen bearing B cell tumor lines can present protein antigen and alloantigen in a major histocompatibility complex-restricted fashion to antigen-reactive T cells. J Exp Med. 1982;155:445-59.
14. Graner M, Raymond A, Romney D, He L, Whitesell L, Katsanis E. Immunoprotective activities of multiple chaperone proteins isolated from murine B-cell leukemia/lymphoma. Clin Cancer Res. 2000;6:909-15.
15. Kim SW, Kim NY, Choi YB, Park SH, Yang JM, Shin S. RNA interference in vitro and in vivo using an arginine peptide/siRNA complex system. J Control Release. 2010;143:335-43.
16. Hong SY, Oh JE, Lee KH. Effect of D-amino acid substitution on the stability, the secondary structure, and the activity of membrane-active peptide. Biochem Pharm. 1999;58:1775-80.
17. Scarfò L, Ghia P. Reprogramming cell death: BCL2 family inhibition in hematological malignancies. Immunol Lett. 2013;155:36-9.
18. Garcia-Garcia C, Draper DE. Electrostatic interactions in a peptide-RNA complex. J Mol Biol. 2003;331:75-88.
19. Crombez L, Charnet A, Morris MC, Aldrian-Herrada G, Heitz F, Divita G. A non-covalent peptide-based strategy for siRNA delivery. Biochem Soc Trans. 2007;35:44-6.
20. Morrissey DV, Lockridge JA, Shaw L, Blanchard K, Jensen K, Breen W, et al. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nature Biotechnol. 2005;23:1002-7.
21. Rea I, Martucci NM, De Stefano L, Ruggiero I, Terracciano M, Dardano P, et al. Diatomite biosilica nanocarriers for siRNA transport inside cancer cells. Biochim Biophys Acta. 1840;2014:3393-403.
22. Noble CO, Kirpotin DB, Hayes ME, Mamot C, Hong K, Park JW, et al. Development of ligand-targeted liposomes for cancer therapy. Expert Opin Ther Targets. 2004;8:335-53.
23. Hu-Lieskovan S, Heidel JD, Bartlett DW, Davis ME, Triche TJ. Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Res. 2005;65:8984-92.
24. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem. 1951;193:265-75.
25. Fiume G, Rossi A, de Laurentiis A, Falcone C, Pisano A, Vecchio E, et al. Eukaryotic initiation factor 4H is under transcriptional control of p65/NF-κB. PLoS One. 2013;8, e66087.